{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Ventures from The Valley","title":"The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-Drory","html":"","width":"100%","height":180,"duration":3633,"description":"What if aging isn’t inevitable — but a solvable problem?And what if the biggest opportunity in healthcare isn’t treating disease, but preventing it entirely?In this episode of Ventures from the Valley, I sit down with Omri Amirav-Drory, General Partner at NFX, to explore one of the most ambitious frontiers in venture capital: longevity, biotech, and the intersection of biology and technology.Omri leads pre-seed and seed investments at NFX and focuses on what he believes is the ultimate mission — ending involuntary death. We talk openly about why aging is the root cause behind most diseases, how AI is transforming biotech, and why longevity represents a $38 trillion per year opportunity in additional healthy life.This is a deep, honest conversation about conviction, risk, optimism, and why the future of healthcare looks nothing like today’s system.⸻In this episode, we discuss: • Why aging is the root cause of 9 out of 10 deadly diseases • The real difference between lifespan and healthspan • Why longevity could unlock $38T per year in economic value • How NFX evaluates early-stage biotech and tech-bio startups • The power-law logic behind seed investing • Why most VCs miss the biggest opportunities by being pessimistic • AI’s three major waves in biotech and drug discovery • Why GLP-1 drugs changed healthcare economics forever • Precision medicine, biomarkers, and the limits of simulation • Whether humans alive today could realistically live to 160 • Replacement biology, regeneration, and the ethics of enhancement❓ Do you believe aging will be cured in our lifetime — or is it science fiction?___________________________________________________________________________R136 Ventures - a Silicon Valley-based multi-stage VC firm with a focus on scaling mid and late-stage B2B and fintech startups.Our mission is to propel creative entrepreneurs to a faster growth trajectory. We help founders scale their mid-to-late stage startups, bringing with us a distinctive fusion of...","thumbnail_url":"https://img.transistorcdn.com/YOcu0kLDdy3azJ6CHb-BvhoJZkdrQney5D7hlI1ejOA/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wYTBh/Y2QwMDRhYzI5NWQw/YzU2Njk2Y2U1MmMy/YTFmYy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}